Celularity Stock Today

CELU Stock  USD 1.55  0.01  0.65%   

Performance

Very Weak

 
Weak
 
Strong

Odds Of Distress

Very High

 
High
 
Low
Celularity is selling for under 1.55 as of the 17th of March 2025; that is 0.65 percent increase since the beginning of the trading day. The stock's last reported lowest price was 1.52. Celularity has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 17th of December 2024 and ending today, the 17th of March 2025. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
8th of August 2019
Category
Healthcare
Classification
Health Care
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey. The company has 23.81 M outstanding shares of which 287.43 K shares are currently shorted by private and institutional investors with about 5.08 trading days to cover. More on Celularity

Moving together with Celularity Stock

  0.61ENVB Enveric Biosciences Earnings Call This WeekPairCorr

Moving against Celularity Stock

  0.81IVA Inventiva SaPairCorr
  0.71LLY Eli LillyPairCorr
  0.57PBH Prestige Brand HoldingsPairCorr
  0.56KRYS Krystal BiotechPairCorr
  0.46MGTX MeiraGTx Holdings PLC Downward RallyPairCorr
  0.35VIGL Vigil NeurosciencePairCorr

Celularity Stock Highlights

President DiseasesStephen DPM
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.170.18
Notably Down
Slightly volatile
Total Current Liabilities39.3 M77.4 M
Way Down
Slightly volatile
Non Current Liabilities Total30.5 M32.1 M
Notably Down
Pretty Stable
Total Assets286.9 M165.5 M
Way Up
Slightly volatile
Total Current Assets28.8 M22.8 M
Significantly Up
Slightly volatile
Debt Levels
Celularity can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Celularity's financial leverage. It provides some insight into what part of Celularity's total assets is financed by creditors.
Liquidity
Celularity currently holds 65.42 M in liabilities with Debt to Equity (D/E) ratio of 0.41, which is about average as compared to similar companies. Celularity has a current ratio of 0.89, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Celularity's use of debt, we should always consider it together with its cash and equity.

Change To Operating Activities

1.53 Million
Celularity (CELU) is traded on NASDAQ Exchange in USA. It is located in 170 Park Avenue, Florham Park, NJ, United States, 07932 and employs 120 people. Celularity is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 36.9 M. Celularity conducts business under Biotechnology sector and is part of Health Care industry. The entity has 23.81 M outstanding shares of which 287.43 K shares are currently shorted by private and institutional investors with about 5.08 trading days to cover. Celularity currently holds about 42.65 M in cash with (38.69 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.29.
Check Celularity Probability Of Bankruptcy
Ownership Allocation
Celularity holds a total of 23.81 Million outstanding shares. Celularity retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Celularity Ownership Details

Celularity Stock Institutional Holders

InstituionRecorded OnShares
Centerstar Asset Management, Llc2024-12-31
22 K
Ipg Investment Advisors, Llc2024-12-31
17.2 K
Renaissance Technologies Corp2024-12-31
11 K
Ground Swell Capital, Llc2024-12-31
10.5 K
Bank Of America Corp2024-12-31
2.3 K
Simplex Trading, Llc2024-12-31
1.5 K
Ubs Group Ag2024-12-31
1.2 K
Ifp Advisors, Llc2024-12-31
1000
Corecap Advisors, Llc2024-12-31
500
C V Starr & Co Inc2024-12-31
764.1 K
Vanguard Group Inc2024-12-31
500.1 K
View Celularity Diagnostics

Celularity Historical Income Statement

At this time, Celularity's Net Income Applicable To Common Shares is comparatively stable compared to the past year. Income Tax Expense is likely to gain to about 12.1 K in 2025, whereas Depreciation And Amortization is likely to drop slightly above 7.3 M in 2025. View More Fundamentals

Celularity Stock Against Markets

Celularity Corporate Management

Carlos RamirezSVP RelationsProfile
Sharmila MDSenior SafetyProfile
CFA CFAChief OfficerProfile
Tim WilkSenior OperationsProfile
Ramji KrishnanChief OfficerProfile
Bradley GloverEx COOProfile
CPA MSTreasurerProfile

Additional Tools for Celularity Stock Analysis

When running Celularity's price analysis, check to measure Celularity's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celularity is operating at the current time. Most of Celularity's value examination focuses on studying past and present price action to predict the probability of Celularity's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celularity's price. Additionally, you may evaluate how the addition of Celularity to your portfolios can decrease your overall portfolio volatility.